drugset

drugset / Trial / NCT00063713

VELCADE in Subjects With Relapsed or Refractory Mantle Cell Lymphoma

NCT00063713 ↗

Phase 2 Completed 152 enrolled Millennium Pharmaceuticals, Inc.

Non-randomizedSingle-groupOpen-labelTreatment

Summary

The purpose of this study is to find out whether treatment with VELCADE will increase the time it takes for lymphoma to get worse.

Timeline

Start: 2003-06
Primary completion: 2005-12
Completion: —

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Bortezomib	Small molecule	—	—

Indications